Showing 1551-1560 of 1735 results for "".
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- MyEyeDr. Partners with CoFi to Streamline Patient Paymentshttps://modernod.com/news/myeyedr-partners-with-cofi-to-streamline-patient-payments/2482673/MyEyeDr., which has 880 locations across the US, has teamed up with multi-party payment provider CoFi to simplify the payment process for patients requiring both optometry and ophthalmology services. This new partnership, now available in all 29 states where MyEyeDr. o
- Qlaris Bio Announces Positive Topline Data From Two Phase 2 Trials of QLS-111 for Glaucomahttps://modernod.com/news/qlaris-bio-announces-positive-topline-data-from-two-phase-2-trials-of-qls-111-for-glaucoma/2482647/Qlaris Bio announced positive topline results from two US phase 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). The trials (Osprey and Apteryx) successfully met all primary and secondary endpoints. Qlaris Bi
- FDA Approves Zeiss MEL 90 Excimer Laserhttps://modernod.com/news/fda-approves-zeiss-mel-90-excimer-laser/2482611/Zeiss has received FDA approval for the MEL 90, giving the excimer laser technology simultaneous approval for all three major indications: myopia, hyperopia, and mixed astigmatism. The Zeiss MEL 90 fully integrates into the company's Corneal Refractive Workflow,
- Ophtec Receives CE Mark Approval for Artiplus Phakic IOL for Presbyopiahttps://modernod.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/Ophtec announced it has received CE Mark approval for its Artiplus Phakic IOL, which is designed for young presbyopes, typically in their early 40s. The Artiplus lens is designed to provide clear vision at all distances, eliminating the need for reading glasses or other corrective
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show